Second Derivative Synchronous Fluorescence Spectroscopy for the Simultaneous Determination of Chlorzoxazone and Ibuprofen in Pharmaceutical Preparations and Biological Fluids

N. El-Enany¹, F. Belal¹, Y. El-Shabrawy², M. Rizk³

¹Department of Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, Egypt; ²Faculty of Pharmacy and Health Science, Ajman University of Science and Technology, United Arab Emirates; ³Department of Analytical Chemistry, Faculty of Pharmacy, University of Helwan, Cairo, Egypt.

ABSTRACT

A rapid, simple and highly sensitive second derivative synchronous fluorometric method has been developed for the simultaneous analysis of binary mixture of chlorzoxazone (CLZ) and ibuprofen (IP). The method is based upon measurement of the synchronous fluorescence intensity of these drugs at Δλ=60 nm in methanol. The different experimental parameters affecting the fluorescence of the two drugs were carefully studied and optimized. The fluorescence-concentration plots were rectilinear over the range of 0.2-4 μg/mL and 0.1-1.6 μg/mL for CLZ and IP, respectively with lower detection limits (LOD) of 0.028  and 8.3 × 10⁻³ μg/mL and quantification limits (LOQ) of 0.086 and 0.03 μg/mL for CLZ and IP, respectively. The proposed method was successfully applied for the determination of the two compounds in synthetic mixtures and in commercial capsules. The high sensitivity attained by the proposed method allowed the determination of both drugs and real human plasma samples. The mean % recoveries in real human plasma (n=3) were 87.69 ± 6.15 and 92.57 ± 4.39 for each of CLZ and IP respectively. (Int J Biomed Sci 2009; 5 (2): 136-145)

Keywords: chlorzoxazone; ibuprofen; synchronous fluorimetry; pharmaceutical preparations and biological fluids

INTRODUCTION

Chlorzoxazone (CLZ), 5-chloro-2(3H)-benzoxazolone (Fig. 1) is a centrally acting muscle relaxant used to treat muscle spasms. It acts on the spinal cord by depressing reflexes (1).

A spectrofluorimetric method (2) has been reported for the determination of CLZ either per se or in pharmaceutical preparations and biological fluids. The United States Pharmacopoeia (USP) recommends spectrophotometric method for its determination in pure form (3) and HPLC method for its determination in tablets.

Ibuprofen (IP) is α-Methyl-4-(2-methylpropyl) benzene-acetic acid (Fig. 1). It is used for relief of symptoms of
Simultaneous synchronous fluorimetric determination of chlorzoxazone and ibuprofen

Regarding ibuprofen, several spectrofluorimetric methods (4-6) have been described for its analysis, whether in dosage forms or in biological fluids. British Pharmacopoeia recommended direct titration against sodium hydroxide using phenolphthaline as indicator for analysis of raw material (7), while USP recommends an HPLC technique for its analysis (7).

The normal synchronous fluorescence spectra of CLZ and IP greatly overlap. This observation led us to utilize second derivative synchronous fluorescence spectroscopy (SDSFS) to solve this problem by measuring peak intensities at 306 and 230 nm for CLZ and IP respectively. The method developed was applied to the simultaneous determination of CLZ and IP in co-formulated pharmaceutical preparation.

Synchronous fluorescence spectroscopy (SFS) has several advantages over conventional fluorescence spectroscopy, including simple spectra, high selectivity and low interference (8). Because of its sharp, narrow spectrum, SFS serves as a very simple, effective method of obtaining data for quantitative determination in a single measurement (9).

The combination of SFS and derivatives is more advantageous than the conventional emission spectrum in terms of sensitivity, because the amplitude of the derivative signal is inversely proportional to the band width of the original spectrum (10, 11).

Recently, derivative synchronous fluorometry (DSF) has been utilized for determination of several mixtures in their co-formulated dosage forms and biological fluids. Thus mixtures of cinnarizine and domperidone (12), metoclopramide and pyridoxine (13), aspirin with salicylic acid (14), diflunisal and salicylic acid (15), carvedilol and ampicillin (16) have been determined through this approach.

To the best of our knowledge, neither conventional nor synchronous spectrofluorometry has been reported for the analysis of CLZ and IP in binary mixtures.

EXPERIMENTAL

Material

Chlorzoxazone and Ibuprofen pure samples were purchased from Sigma (St. Louis, Mo, USA) and used as received. Myofen capsules labeled to contain 250 mg of CLZ and 200 mg of IP in a ratio of 5:4 (Batch # 604346) was obtained from commercial source in the local market.

Reagents

All reagents and solvents were of Analytical Reagent Grade.

- Methanol (Merck, Darmstadt, Germany). Acetate buffer 0.2 M (pH3.6-5.6) was prepared by mixing appropriate volume of 0.2 M acetic acid with 0.2 M sodium acetate. Borate buffers (pH6-9.5) were prepared by mixing appropriate volumes of 0.02 M boric acid with 0.2 M sodium hydroxide.
- Chloroform (Aldrich, St. Louis, MO, USA). Phosphate buffer (pH7.4) was prepared by mixing appropriate volume of 0.2 M KH₂PO₄ with 0.1 M sodium hydroxide (17).
- Sodium hydroxide ((BDH, UK), 0.1 M aqueous solution.

Apparatus

Fluorescence spectra and measurements were recorded using a Perkin-Elmer UK model LS 45 luminescence spectrometer, equipped with a 150 Watt Xenon arc lamp, grating excitation and emission monochromators for all measurements and a Perkin-Elmer recorder. Slit widths for both monochromators were set at 10 nm. A 1 cm quartz cell was used. Derivative spectra can be evaluated using Fluorescence Data Manager (FLDM) software.

For best resolution and smoothing, use number of points of 99 for deriving the second derivative spectra. The fluorescence intensities of the second derivative spectra were estimated at 306 nm and 230 nm for CLZ and IP, respectively.

A pH Meter (Model pHS-3C, Shanghai Leici instruments Factory, China) was used for pH adjustment.

Standard Solutions

Stock solutions of CLZ and IP were prepared by dissolving 10.0 mg of the studied compounds in 100 mL of methanol and were further diluted with the same solvent as appropriate. The standard solutions were stable for 10 days when kept in the refrigerator.

RECOMMENDED PROCEDURES

Calibration curve

Aliquots of CLZ and IP standard solutions covering the working concentration range cited in table 1 were transferred into a series of 10 mL volumetric flasks. Two mL of borate buffer (pH7.0) was added and the solutions were diluted to the volume with methanol and mixed well. Synchronous fluorescence spectra of the solutions were...
recorded by scanning both monochromators at a constant wavelength difference $\Delta \lambda = 60$ nm and scan rate of 600 nm min$^{-1}$ using 10 nm excitation and emission windows. The second derivative fluorescence spectra of CLZ and IP was derived from the normal synchronous spectra using FLDM software. The peak amplitude of the second derivative spectra was estimated at 306 nm and 230 nm for CLZ and IP, respectively. A blank experiment was performed simultaneously. The peak amplitude of the second derivative technique was plotted vs the final concentration of the drug ($\mu$g/mL) to get the calibration graph. Alternatively, the corresponding regression equations were derived.

**Procedure for the synthetic mixture**

Aliquot volumes of CLZ and IP standard solutions in the ratio of 5:4 were transferred into a series of 10 mL volumetric flasks. Two mL of borate buffer (pH7.0) was added followed by dilution to the volume with methanol, and mixed well. The recommended procedure under calibration curve was then performed. The peak amplitude of the second derivative technique was plotted vs the final concentration of the drug ($\mu$g/mL) to generate the calibration graph. Alternatively, the corresponding regression equations were derived.

**Applications**

**Procedure for commercial capsules.** The contents of 10 capsules were emptied and mixed well. A weighed quantity of the powder equivalent to 10.0 mg CLZ and 8.0 mg of IP (in their pharmaceutical ratio of 5:4) was transferred into a small conical flask and extracted with 3 $\times$ 30 mL of methanol. The extract was filtered into a 100 mL volumetric flask. The conical flask was washed with few mLs of methanol. The washings were passed into the same volumetric flask and completed to the mark with the same solvent. Aliquots covering the working concentration range were transferred into 10 mL volumetric flasks. The recommended procedure under "Calibration Curve" was performed. The nominal content of the capsules were determined either from a previously plotted calibration graph or using the corresponding regression equation.

**Procedure for real human plasma.** Myofen capsule (250 mg CLZ and 200 mg IP/capsule) was orally administered to healthy fasting volunteer (male, 40 years old). 5 mL of blood sample was withdrawn after two hours, 4 mLs of citrate solution were added, and centrifuged at 3500 rpm for 15 min. to obtain 3.0 mL of plasma. One mL aliquots of the plasma were transferred into separating funnels. Two mL of phosphate buffer (pH7.4) was added to each funnel. The contents were mixed, then extracted with 3 $\times$ 5 mL of chloroform. The organic layer was passed over anhydrous sodium sulphate and evaporated till dryness. The residue was dissolved in 10 mL of methanol. The recommended procedure under “Calibration Curve” was performed. A blank experiment was carried out simultaneously. Determine the nominal content of CLZ and IP using the following equation:

$$\text{Recovery}_{in\,vivo} = \frac{\text{Delivery}_{in\,vivo} \times \text{Recovery}_{in\,vivo}}{\text{Delivery}_{in\,vivo}}$$

This means that % recovery for CLZ or IP in real human plasma = Concentration of the drug in real plasma X % recovery in spiked plasma/Concentration of the drug in spiked plasma

**RESULTS AND DISCUSSION**

**SDSF spectra of CLZ and IP**

Both CLZ and IP exhibit native fluorescence with $\lambda$ maximum of 312 nm and 295 nm, after excitation at 285 nm for CLZ and 231 for IP respectively (Fig. 2). Both the excitation and emission spectra of CLZ and IP overlapped (Fig. 2). This fact hindered the use of this method for the simultaneous determination of CLZ and IP. This problem is aggravated if it is desired to determine these compounds in their co-formulated preparations and biological fluids.

It was necessary to first record, the normal synchronous spectra for CLZ and IP in order to derive the second derivative synchronous spectra. Fig. 3 shows the SF spectra of different concentrations of CLZ at 283 nm in presence of constant concentration IP (0.6 $\mu$g/mL), whereas, Fig. 4 illustrates the SF spectra of different concentrations of IP at 230 nm in presence of constant concentration of CLZ (4.0 $\mu$g/mL).

Therefore we performed the SDSFS technique for simultaneous determination of each of CLZ and IP in their capsules. Spectra of CLZ and IP were well separated using SDSFS with a zero-crossing technique of measurement (Figs. 5 and 6). Under the experimental conditions the two peaks appeared at 306 and 230 nm for CLZ and IP respectively.

**Optimization of Reaction condition**

Different experimental parameters affecting the performance of the proposed method were carefully studied and optimized. Such factors were changed individually while others were kept constant. These factors included
selection, pH, type of the diluting solvent, stability time and ionic strength.

**Selection of optimum $\Delta \lambda$**

The optimum $\Delta \lambda$ value is important for performing the synchronous fluorescence scanning technique with regard to its resolution, sensitivity and features. It can directly influence spectral shape, band width and signal value. For this reason a wide range of $\Delta \lambda$ (20, 40, 60, 80, 100 and 120 nm) was examined. When $\Delta \lambda$ was less than 60 nm, the spectra shape were irregular, noisy and the fluorescence intensity is very weak. When $\Delta \lambda$ was more than 60 nm, overlapping of the two peaks with poor separation was achieved. Therefore, $\Delta \lambda$ of 60 was chosen as optimal for separation of CLZ and IP mixtures, since it resulted in two distinct peaks with good regular

![Figure 2](image2.png)

**Figure 2.** Normal fluorescence spectra at pH 7.0. a, (A, A') are excitation and emission spectra of CLZ (1.0 μg/mL); b, (B, B') are excitation and emission spectra of IP (0.8 μg/mL).

![Figure 3](image3.png)

**Figure 3.** Synchronous fluorescence spectra of CLZ at 283 nm and IP. (1), spectrum of IP (0.6 μg/mL); (2), a-h spectra of CLZ (0.2, 0.4, 0.5, 0.8, 1, 2, 3 and 4 μg/mL) respectively.

![Figure 4](image4.png)

**Figure 4.** Synchronous fluorescence spectra of IP at 230 nm and CLZ. (1) Spectrum of CLZ (4.0 μg/mL); (2) a-f Spectra of IP (0.1, 0.2, 0.4, 0.6, 0.8 and 1.6 μg/mL) respectively.
shapes and reduced the spectral interference caused by each compound.

**Effect of pH**

The influence of pH on the fluorescence intensity of the studied drugs was studied using different buffers covering the whole pH range, e.g. acetate buffer over the pH range of 3.6-5.6 and borate buffer over the pH range 6-9.5. The synchronous fluorescence intensity of CLZ remained constant with the increase of pH from 3.6 up to pH 7. Fluorescence intensity decreased at pH 7.5, then it increased at pH 10.0, after which it decreased gradually up to pH 13 (Fig. 7). As for IP, increasing the pH values resulted in a gradual increase in the synchronous fluorescence intensity up to 7.0, then remained constant up to pH 9.50, after which it slightly increased at pH 13 (Fig. 7). Therefore, borate buffer of pH 7.0 was used throughout the study.

**Effect of volume of buffer**

Increasing volume of borate buffer (pH 7.0) resulted in a gradual increase in the synchronous fluorescence intensity of CLZ and IP up to 2 mL after which the fluorescence intensity remained constant till 4 mL. Therefore, 2mL of borate buffer (pH 7.0) was chosen as the optimum buffer volume.

**Effect of diluting solvent**

Dilution with different solvents including water, methanol, isopropanol, dimethyl sulfoxide (DMSO), tetrahydrofurane (THF) and dimethyl formamide (DMF) was employed. Of the all tested solvents methanol gave the...
heighest synchronous fluorescence intensities compared with the other solvents. Thus, methanol was chosen as the diluting solvent through out the study.

**Effect of time**

The effect of time on the stability of the synchronous fluorescence intensity of the drugs was also studied. It was found that the fluorescence intensity developed instantaneously and remained stable for more than 2 hours.

**Analytical Performance**

The second derivative synchronous fluorescence spectroscopy-concentration plots for the two drugs were linear over the concentration range cited in Table 1. Linear regression analysis of the data gave the following equations:

\[
D^2 = -0.106 + 17.50C \quad (r=0.9999)
\]

for CLZ at 306 nm With \(S_a=0.15\) and \(S_b=0.069\)

\[
D^2 = 0.846 + 206.0C \quad (r=0.9999)
\]

for IP at 230 nm With \(S_a=0.52\) and \(S_b=0.659\)

where \(D^2\) is the second derivative synchronous fluorescence spectroscopy, \(C\) is the concentration of the drug (µg/mL) and \(r\) is correlation coefficient.

The limit of quantification (LOQ) was determined by establishing the lowest concentration that can be measured according to ICH Q2B recommendations (19), below which the calibration graph is non linear. The limit of detection (LOD) was determined by evaluating the lowest concentration of the analyte that can be readily detected. The results of LOD and LOQ of CLZ and IP by SDSFS method are abridged in Table 1.

**Table 1. Performance data of the proposed method**

| Parameter               | Chloroxazone | Ibuprofen  |
|-------------------------|--------------|------------|
| Concentration range (µg/mL) | 0.2-4.0      | 0.1-1.6    |
| Correlation coefficient | 0.9998       | 0.9999     |
| Slope                   | 17.50        | 206.0      |
| Intercept               | -0.106       | 0.846      |
| Limit of detection (LOD) (µg/mL) | 0.028   | \(8.3 \times 10^{-3}\) |
| Limit of Quantification (LOQ) (µg/mL) | 0.086 | 0.03 |
| \(S_y\)                 | 0.243        | 0.52       |
| \(S_a\)                 | 0.15         | 0.52       |
| \(S_b\)                 | 0.069        | 0.659      |
| %RSD                    | 1.06         | 1.16       |
| %Error                  | 0.4          | 0.473      |

\(S_y\), Standard deviation of the residuals; \(S_a\), Standard deviation of the intercept % RSD=Relative standard deviation; \(S_b\), Standard deviation of the slope % Error= %RSD/√n.

LOQ and LOD were calculated according to ICHQ2 recommendations (19):

- **LOQ=10 \(\sigma/S\)**
- **LOD=3.3 \(\sigma/S\)**

\(S\) is the slope and \(\sigma\) is the standard deviation of the intercept of regression line of the calibration curve.

The proposed method was evaluated by studying the accuracy as percent relative error and precision as percent relative standard deviation. The results are abridged in Table 1.

Statistical analysis (20) of the results, obtained by the proposed and the official or reference methods (3,5) using Student’s t-test and variance ratio F-test, shows no significant difference between the performance of the two methods regarding the accuracy and precision, respectively (Table 2). The reference method is based on the host-guest complexation between \(\beta\)-cyclodextrin (\(\beta\)-CD) and ibuprofen. The fluorescence of the resulted complex was measured at 290 nm after excitation at 230 nm (5).

**Analysis of synthetic mixture of CLZ and IP**

The proposed method was applied to the simultaneous determination of CLZ with IP in synthetic mixtures containing different concentrations of both drugs in a ratio of 5:4 (Fig. 8). The relative fluorescence intensities of second derivative technique were measured for both drugs. The second derivative signal of CLZ was measured at 306 nm which is considered as zero crossing point for IP and the second derivative signal for IP was measured at 230 nm which is the zero crossing point for CLZ. The concentrations of both drugs in the synthetic mixture were calculated according to the linear regression equation of the calibration graphs. The results indicate high accuracy of the proposed method as shown in Table 3.

**Validation of the Method**

The validity of the method was tested regarding; linearity, specificity, accuracy, repeatability and precision according to ICH Q2B recommendations. (19).

**Linearity**

The regression plots showed a linear dependence of \(D^2\) values on drug concentration over the range cited in table 1.

**Accuracy**

The proposed methods were applied to the determination of authentic sample of CLZ and IP over the concentration range cited in Table 2 in order to determine their
The results obtained were in good agreement with those obtained using official (3) and reference methods (5). Using the Student’s t-test and the variance ratio F-test, (20) revealed no significant difference between the performance of the two methods regarding the accuracy and precision, respectively (Table 2).

The validity of the methods was proved by statistical evaluation of the regression lines, using the standard deviation of the residuals ($S_{y|x}$), the standard deviation of the intercept ($S_a$) and standard deviation of the slope ($S_b$). The results are abridged in Table 1. The small values of the figures point out to the low scattering of the points around the calibration line and high precision.

### Precision

**Repeatability.** The repeatability was performed by applying the proposed methods for the determination of two concentrations of CLZ and IP in pure forms on three successive times, and the results are listed in Table 4.

**Intermediate precision.** Intermediate precision was evaluated through repeated analysis of CLZ and IP in pure form applying the proposed method, using the concentrations showed in Table 4, for a period of 3 successive days.

### Table 2. Application of the second derivative synchronous fluorimetry to the determination of the studied drugs in the pure form

|                | Concentration taken (µg/mL) | Concentration found (µg/mL) | % Found | Official or Reference methods (3, 5) |
|----------------|----------------------------|-----------------------------|---------|-------------------------------------|
| **1-CLZ**      |                            |                             |         |                                     |
| 0.2            | 0.2015                     | 100.75                      | 98.30   |
| 0.5            | 0.4919                     | 98.38                       | 100.53  |
| 0.8            | 0.7891                     | 98.64                       | 100.86  |
| 1.0            | 1.008                      | 100.80                      | 99.43   |
| 2.0            | 2.018                      | 100.90                      |         |
| 3.0            | 2.981                      | 99.37                       |         |
| 4.0            | 4.006                      | 100.15                      |         |
| **X’**         |                            |                             | 99.86   | 99.78                               |
| **SD**         |                            |                             | 1.06    | 1.16                                |
| **t-test**     |                            |                             | 0.116 (2.26) | 1.2 (4.76) |
| **F value**    |                            |                             |         |                                     |
| **2-IP**       |                            |                             |         |                                     |
| 0.1            | 0.0988                     | 98.80                       | 98.65   |
| 0.2            | 0.2024                     | 101.20                      | 100.01  |
| 0.4            | 0.3986                     | 99.65                       | 99.74   |
| 0.6            | 0.5970                     | 99.50                       | 100.17  |
| 0.8            | 0.8081                     | 101.01                      |         |
| 1.6            | 1.5730                     | 98.32                       |         |
| **X’**         |                            |                             | 99.75   | 99.64                               |
| **SD**         |                            |                             | 1.16    | 0.69                                |
| **t-test**     |                            |                             | 0.169 (2.31) | 2.84 (5.41) |
| **F value**    |                            |                             |         |                                     |

Figures between parenthesis are the tabulated t and F values, respectively at $p=0.05$ (20).
The robustness of the method

The robustness of the proposed method is demonstrated by the constancy of the fluorescence intensity with the deliberated changes in the experimental parameters such as pH, 5 ± 1 for CLZ and pH, 8 ± 1 for IP, change volume of methanol and volume of buffer 3 ml ± 1. This minor change that may take place during the experimental operation didn’t greatly affect the fluorescence intensity of the mixture.

Pharmaceutical Applications

The proposed method was applied to the determination of the studied drugs in their coformulated capsules. The specificity of the method was investigated by observing any interference encountered from the common excipients, such as lactose, gelatin, magnesium stearate and starch. These excipients did not interfere with the proposed method (Table 5).

Biological applications

The high sensitivity of the proposed method allowed the determination of CLZ and IP in biological fluids by SDSFS method. The method was further applied to the in-vivo determination of both drugs in real human plasma.

IP is absorbed from gastro-intestinal tract. Following oral ingestion of a single oral dose of 250 mg CLZ and 200 mg IP, IP give a mean peak plasma 20-30 mg/L attained in about 1.1 hour (21). This value lies above the working concentration range of the proposed method. Thus they could be determined by the proposed method. The method involved extraction with chloroform. The extraction procedure described by Glowka et al (22) was adopted.

Table 3. Application of the proposed method for determination of the studied drugs in their synthetic mixtures

| Sample                | Concentration taken (μg/mL) | Concentration found (μg/mL) | Recovery % |
|-----------------------|-----------------------------|-----------------------------|------------|
|                       | CLZ | IP | CLZ | IP | CLZ | IP | CLZ | IP |
| CLZ and IP mixture    | 0.25| 0.2| 0.2529| 0.2014| 101.16| 100.70|
|                       | 0.50| 0.4| 0.5088| 0.4015| 101.76| 100.38|
|                       | 0.75| 0.6| 0.7490|       | 99.87 | 100.23|
|                       | 1.0 | 0.8| 1.0124| 0.7873| 101.24| 98.41 |
| X^+                                |     |     | 100.47| 99.93 | ± 1.03| ± 1.03|
| ± SD                               |     |     |       |       | % RSD 1.03 | 1.03|
| % Error                           |     |     |       |       |       | 0.515| 0.515|

Each result is the average of three separate determinations.

Table 4. Validation of the proposed method for determination of CLZ and IP raw materials using SDSFS mode

| Concentration added (μg/ml) | % Recovery | % RSD | % Error |
|-----------------------------|------------|-------|---------|
|                             | CLZ        |       |         |
| Intra-day                   |            |       |         |
| 1.0                         | 100.31 ± 0.53| 0.53 | 0.31    |
| 2.0                         | 99.82 ± 0.70| 0.70 | 0.40    |
| Inter-day                   |            |       |         |
| 1.0                         | 99.92 ± 0.80| 0.80 | 0.46    |
| 2.0                         | 100.15 ± 0.76| 0.76| 0.44    |
|                             | IP         |       |         |
| Intra-day                   |            |       |         |
| 0.80                        | 100.72 ± 0.24| 0.24| 0.14    |
| 1.60                        | 100.63 ± 0.53| 0.53| 0.31    |
| Inter-day                   |            |       |         |
| 0.80                        | 100.72 ± 0.79| 0.79| 0.46    |
| 1.60                        | 100.62 ± 0.78| 0.78| 0.45    |

Each result is the average of three separate determinations.

The within-day precision was evaluated through replicate analysis of real plasma containing CLZ and IP. The mean percentage recoveries based on the average of three separate determinations were 87.69 ± 6.15 and 92.57 ± 4.39 for CLZ and IP respectively. The results are abridged in table 6.

CONCLUSION

A new simple and sensitive method was explored for the simultaneous determination of CLZ and IP in binary
SIMULTANEOUS SYNCHRONOUS FLUORIMETRIC DETERMINATION OF CHLORZOXAZONE AND IBUPROFEN

Table 5. Application of the proposed method for determination of the studied drugs in their co-formulated preparations

| Preparation | Concentration taken (μg/mL) | Concentration found (μg/mL) | Recovery % |
|-------------|-----------------------------|-----------------------------|------------|
|             | CLZ | IP | CLZ | IP | CLZ | IP |               |               |
| Myofen capsules † | 0.25 | 0.20 | 0.2497 | 0.2026 | 99.88 | 101.30 |               |               |
| (CLZ 250 mg + IP 200 mg/capsule) | 0.50 | 0.40 | 0.4928 | 0.3936 | 98.56 | 98.40 |               |               |
| Batch # 604346 | 0.75 | 0.60 | 0.7569 | 0.5950 | 100.92 | 99.17 |               |               |
| x |               |               | ± SD | ± 1.18 | ± 1.50 |               |               |
| % RSD |               |               | 1.18 | 1.50 |               |               |
| % Error |               |               | 0.68 | 0.87 |               |               |

Each result is the average of three separate determinations. † Product of Eva Pharma for Pharmaceuticals and Medical Appliances S.A.E. Egypt.

Table 6. Application of the proposed method for determination CLZ and IP in real human plasma

| Sample | Amount taken (μg/mL) | Amount found (μg/mL) | % Found |
|--------|----------------------|----------------------|---------|
|        | CLZ | IP | CLZ | IP | CLZ | IP |               |               |
| Real Plasma | 0.25 | 0.20 | 0.2182 | 0.1788 | 87.28 | 89.40 |               |               |
|        | 0.50 | 0.40 | 0.4702 | 0.3629 | 94.04 | 90.73 |               |               |
|        | 1.0 | 0.80 | 0.8176 | 0.7806 | 81.76 | 97.58 |               |               |
| x |               |               | ± SD | ± 6.15 | ± 4.39 |               |               |
| % RSD |               |               | 6.15 | 4.39 |               |               |
| % Error |               |               | 3.55 | 2.53 |               |               |

mixture. The second derivative synchronous spectrofluorometric method, by virtue of its high sensitivity, could be applied to the analysis of both drugs in their co-formulated dosage forms and biological fluids; it was possible to measure as concentrations low as 0.086 and 0.03 μg/mL for CLZ and IP respectively with good accuracy. Moreover, second derivative spectrofluorimetric technique enables the determination of CLZ in the presence of IP by applying the zero-crossing technique in the spectra without prior separation steps. Moreover, the proposed method is time saving.

REFERENCES

1. Kleemann, Engels. Encyclopedia of Pharmaceutical Substances. 2000; 4th ed.
2. Stewart JT, Chan CW. Fluorometric determination of chlorzoxazone in tablets and biological fluids. J. Pharm. Sci. 1979; 68: 910-912.
3. The United States Pharmacopoeia. The US Pharmaceutical Convention, NF 27. Rockville. 2004; 440, 441: 2740.
4. Hergert LA, Escandar GM. Spectrofluorimetric study of the β-cyclodextrin–ibuprofen complex and determination of ibuprofen in pharmaceutical preparations and serum. Talanta. 2003; 60: 235-246.
5. Manzoori JL, Amjadi M. Spectrofluorimetric study of host–guest complexation of ibuprofen with β-cyclodextrin and its analytical application. Spectrochim Acta. A Mol. Biomol. Spectrosc. 2003; 59: 909-916.
6. Sadecka J, Cakrt M, Hercegova A, Polonsky J, et al. Determination of ibuprofen and naproxen in tablets. J. Pharm. Biomed. Anal. 2001; 25: 881-891.
7. The British Pharmacopoeia. Incorporating requirement of 5th edition of the European Pharmacopoeia 2004 as amended by supplement, through electronic version. London: Stationary Office. 2007.
8. Chen GZ, Huang XZ, Xu JG, Zheng ZZ, et al. The Methods of Fluorescence Analysis, 2nd Ed. Beijing: Science Press. 1990; p112.
9. Patra D, Mishra AK. Recent development in multicomponent synchronous fluorescence scan analysis. Trends Anal. Chem. 2002; 21: 787.
10. Lloyd JBF. Nat Phys. Sci. 231:64. http://www.chemistrymag.org/eji/2003/058065pe.htm. 2003; vol. 5 No. 8:65.
11. Murillo Pulgarin JA, Alanon Molina A, Fernandez Lopez P. Simultaneous determination of atenolol, propranolol, dipyridamole and amiloride by means of nonlinear variable angle synchronous fluorescence spectrometry. Anal. Chim. Acta. 1998; 370: 9-18.
12. Walash MI, Belal F, El-Enany N, Abdelal AA. Second derivative synchronous fluorometric method for the simultaneous determination of cinnarizine and domperidone in pharmaceutical preparations. Application to biological fluids. J. Fluoresc. 2008; 18: 61-74.
13. El-Enany N. Second derivative synchronous fluorescence spectroscopy for the simultaneous determination of metoclopramide and pyridoxine in syrup and human plasma. J. AOAC. INT. 2008; 91: 542-550.
14. Wei YF, Li XH, Ma DM. Simultaneous determination of aspirin and salicylic acid by synchronous fluorescence spectrometry. Guang Pu Xue Yu Guang Pu Fen Xi. 2005; 25: 588-590.
15. Murillo Pulgarín JA, Alañón Molina A, Fernández López P, Sánchez-Ferrer Robles I. Direct determination of closely overlapping drug mixtures of diflunisal and salicylic acid in serum by means of derivative matrix isopotential synchronous fluorescence spectrometry. Anal. Chim. Acta. 2007; 583: 55-62.
16. Xiao Y, Wang HY, HAN J. Simultaneous determination of carvedilol and ampicillin by synchronous fluorimetry. Acta. A Mol. Biomol. Spectrosc. 2005; 61: 567-573.
17. Perrin DD, Dempsey B. Buffers for pH and Metal Ion Control. Chapter 10, Appendix II, New York: Wiley. 1974; p139.
18. Sun Y, Nakashima MN, Takahashi M, Kuroda N, et al. Determination of bisphenol A in rat brain by microdialysis and column switching high-performance liquid chromatography with fluorescence detection. Biomed. Chromatogr. 2002; 16: 319-326.
19. Guidance for Industry; Q2B of Analytical Procedures: Methodology; International Conference on Harmonization (ICH), November 1996. http://www.fda.gov/eder/guidance/1320fnl.pdf (accessed September 1, 2004).
20. Miller JC, Miller JN. Statistics and Chemometrics for Analytical Chemistry. 5th ed. England: Prentice Hall. 2005.
21. Moffat AC, Osselton MD, Widdop B, Galichet LY. Clark’s Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material, 3rd ed. London: The Pharmaceutical Press. Vol II. 2004.
22. Glowka KF, Karazniewicz M. High performance capillary electrophoresis method for determination of ibuprofen enantiomers in human serum and urine. Anal. Chim. Acta. 2005; 540: 95-102.